{"entity":{"id":"iomab-b","kind":"drug","name":"Iomab-B","aka":["Apamistamab-I131","131I-apamistamab"],"tldr":"Iomab-B is Actinium's radioactive antibody that clears the bone marrow before a transplant for older patients with active relapsed acute myeloid leukaemia; the phase 3 SIERRA trial met its primary endpoint but the FDA asked for another study.","summary":"Iomab-B delivers iodine-131 to CD45-positive cells, allowing patients with relapsed or refractory acute myeloid leukaemia who would not tolerate conventional myeloablative conditioning to proceed to allogeneic transplant. In the phase 3 SIERRA trial, Iomab-B followed by transplant produced durable complete remission at six months in a substantially higher share of patients than conventional care. Actinium reported in 2024 that the FDA requested an additional randomised trial before filing, and it is seeking partners; the trial is recorded here.","status":"phase-3","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Iomab-B","url":"https://clinicaltrials.gov/search?intr=Iomab-B"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":["radioimmunotherapy","radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct02665065"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"modality":"Radioimmunotherapy conditioning agent (anti-CD45 antibody labelled with iodine-131)","mechanism":"An antibody against CD45, found on all white blood cells, carries iodine-131 to the marrow and leukaemia cells and ablates them in place of high-dose chemotherapy before a stem cell transplant.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/iomab-b/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"technology":[{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"trial":[{"id":"nct02665065","kind":"trial","name":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct02665065/"}]}}